Gravitas: Biocon executives charged with bribing regulators

Indian pharma giant Biocon has been accused of bribing regulators to speed up the approval of their insulin product. 

In response to WION's report, Biocon has issued a statement. "We strongly condemn any acts of corruption and violation of rules by way of offering or paying bribes or undue favours, either directly or indirectly. We adopt global best practices in corporate governance and business responsibility," it read. 

Open this PDF file and read the full statement.